首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFSF13 |
| Uniprot No | O75888 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 105-250aa |
| 氨基酸序列 | AVLTQKQKKQ HSVLHLVPIN ATSKDDSDVT VMWQPALRR GRGLQAQGYG VRIQDAGVYL LYSQVLFQDV TFTMGQVVSR EGQGRQETLF CIRSMPSHP DRAYNSCYSA GVFHLHQGDI LSVIIPRARA KLNLSPHGTF LGFVKL |
| 预测分子量 | 20 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFSF13重组蛋白的3篇参考文献，包含文献名称、作者及摘要概括：
---
1. **文献名称**: *"Structural and functional analysis of recombinant TNFSF13 (APRIL) in B cell activation"*
**作者**: Dillon SR et al.
**摘要**: 研究通过重组表达纯化TNFSF13蛋白，解析其晶体结构，发现其通过结合BCMA和TACI受体激活NF-κB通路，促进B细胞增殖及抗体分泌，为自身免疫疾病治疗提供靶点依据。
---
2. **文献名称**: *"Recombinant TNFSF13 enhances survival and proliferation in multiple myeloma cells"*
**作者**: Moreaux J et al.
**摘要**: 利用重组TNFSF13蛋白处理多发性骨髓瘤细胞，证明其通过抑制凋亡信号并上调抗凋亡蛋白(如MCL-1)表达，显著增强癌细胞存活，提示靶向TNFSF13或可改善相关癌症治疗。
---
3. **文献名称**: *"TNFSF13 as a therapeutic target in autoimmune disorders: Insights from recombinant protein models"*
**作者**: Stohl W et al.
**摘要**: 通过动物模型验证重组TNFSF13蛋白在系统性红斑狼疮(SLE)中的作用，发现其过度表达导致自身抗体水平升高;使用中和抗体阻断TNFSF13可缓解疾病症状，支持其作为自身免疫病干预靶点。
---
**备注**：以上文献信息为示例性概括，实际文献需通过PubMed或Web of Science等平台检索(建议结合关键词如“TNFSF13 recombinant protein”或“APRIL B cell”)。如需具体文献，可提供PMID编号进一步定位。
**Background of TNFSF13 Recombinant Protein**
TNFSF13 (tumor necrosis factor superfamily member 13), also known as APRIL (A Proliferation-Inducing Ligand), is a cytokine belonging to the TNF superfamily. It is primarily produced by immune cells, including macrophages, dendritic cells, and neutrophils, and plays a critical role in regulating B-cell proliferation, survival, and antibody production. APRIL binds to two receptors: BCMA (B-cell maturation antigen) and TACI (transmembrane activator and calcium-modulator ligand interactor), which are expressed on B lymphocytes and plasma cells. This interaction activates signaling pathways, such as NF-κB, promoting immune responses and maintaining humoral immunity.
Recombinant TNFSF13 protein is engineered using biotechnological methods, typically expressed in mammalian or bacterial systems to ensure proper folding and post-translational modifications (e.g., glycosylation). Purified recombinant APRIL retains its biological activity, enabling its use in research to study autoimmune diseases (e.g., systemic lupus erythematosus), B-cell malignancies, and immune dysregulation. It is also explored therapeutically; for example, APRIL-neutralizing antibodies are investigated for treating conditions driven by excessive B-cell activity.
Additionally, TNFSF13 has been implicated in cancer progression, particularly in multiple myeloma and lymphoma, where aberrant signaling supports tumor survival. Recombinant APRIL serves as a tool to dissect these mechanisms and screen potential inhibitors. Its role in mucosal immunity and inflammation further underscores its relevance in vaccine development and infectious disease research.
In summary, TNFSF13 recombinant protein is a vital reagent for understanding immune regulation, disease pathogenesis, and therapeutic targeting, bridging basic research with clinical applications.
×
